Promecens Entosystems and Shield Nutraceuticals are evaluating the development of a modular mushroom chitosan biorefinery designed to support the next generation of sustainable, non-shellfish chitosan production.
The proposed Phase 1 facility would be co-located with Bioferment.tech and developed through a brownfield strategy that leverages an existing substrate line, site infrastructure, utilities and environmental framework.
The project is intended to establish a scalable platform for manufacturing mushroom-derived chitosan for pharmaceutical, cosmetic, nutraceutical and industrial applications. The proposed production model also includes potential co-products such as beta-glucan concentrate, mycelium protein meal and organic soil amendments.
The preliminary Phase 1 plan includes:
The proposed facility would be developed to support high-purity production and a modular pathway from pilot-scale validation to broader commercial manufacturing.
All capital, operating, production and revenue figures are preliminary management estimates and remain subject to technical, commercial and financial due diligence.
Conventional chitosan is commonly manufactured from marine shellfish by-products. Although shellfish-derived chitosan remains widely used, manufacturers and product developers are increasingly evaluating alternative sources that may offer more consistent feedstock availability, improved batch repeatability and a non-shellfish supply profile.
Mushroom-derived chitosan may provide several potential advantages:
The proposed operation would compete primarily through quality, specialization and product-grade differentiation rather than commodity-scale pricing alone.
The Phase 1 investment strategy is structured around six principal drivers.
The preliminary plan targets a $3.5 million investment within a 25,000–30,000-square-foot operating footprint.
The modular facility configuration could create a pathway toward future expansion without requiring a complete redesign of the original production system.
The proposed process combines enzymatic treatment, microwave-assisted processing, solvent recovery and in-house analytical testing.
Compared with the conventional shellfish-processing baseline used in the preliminary model, the proposed system is targeting substantially lower fresh-water consumption, lower energy demand, shorter batch cycles and the elimination of toxic liquid effluent at the partner site.
These targets must be confirmed through pilot-scale validation and engineering review.
Co-location with Bioferment.tech is intended to provide access to existing infrastructure, including:
Preliminary management estimates indicate that this strategy could reduce site-preparation costs by approximately 40% compared with developing a standalone greenfield facility.
The proposed implementation schedule targets approximately 12 months from initial capital deployment to the first commercial shipment.
Progression through the project would be controlled through clearly defined engineering, installation, qualification and pilot-production gates.
The proposed facility is intended to produce multiple chitosan grades from a common substrate stream.
Pharmaceutical-grade mushroom chitosan with a target degree of deacetylation of at least 98% is preliminarily positioned within a target price range of approximately $70–$100 per kilogram.
Final pricing would depend on verified specifications, testing requirements, customer qualification, order volume and prevailing market conditions.
The facility would use modular processing zones supported by formal quality and qualification systems.
The proposed controls include:
This approach is intended to reduce scale-up risk and allow additional capacity to be introduced only after the initial process has been validated.
The proposed brownfield co-location strategy is not based solely on reducing construction costs. It is intended to connect the Phase 1 facility with an existing substrate supply, utility infrastructure, workforce and environmental framework.
Bioferment.tech’s existing operations may provide a degree of site readiness that would otherwise need to be developed independently.
This may include:
The final project structure would remain subject to site surveys, legal agreements and regulatory review.
Steam, water, refrigeration and effluent pre-treatment are expected to be available through the partner site.
This would allow more of the Phase 1 capital to be directed toward:
The preliminary project model assumes that certain site requirements may be addressed through amendments to existing permits rather than entirely new applications.
The indicative permitting window is approximately six to nine months, subject to confirmation by the relevant authorities.
The proposed biorefinery would receive feedstock from Bioferment.tech’s substrate line.
A connected supply arrangement may reduce the need for:
A long-term supply agreement would be required to establish volume commitments, quality requirements and appropriate inventory protections.
Demand for specialized chitosan is influenced by pharmaceutical, cosmetic, agricultural, water-treatment and clean-technology applications.
Potential demand drivers include:
The proposed operation would seek to address these markets through specialized grades rather than a single commodity product.
The Phase 1 revenue model is based on manufacturing several chitosan grades from a common substrate stream.
| Proposed chitosan grade | Preliminary target price |
|---|---|
| Pharmaceutical grade, target ≥98% DD | $70–$100/kg |
| Cosmetic grade | $35–$55/kg |
| Industrial grade | $18–$28/kg |
A multi-grade production strategy could provide greater operational flexibility. Production may be directed toward the grade offering the most suitable combination of verified yield, product demand and commercial margin.
All pricing remains preliminary and must be confirmed through product qualification and commercial agreements.
The proposed extraction process may also generate materials that could be developed as commercial co-products.
Residual biomass from the extraction process may be evaluated as a protein-rich ingredient for aquaculture or pet-food applications.
Commercial use would depend on composition testing, safety evaluation and applicable regulatory requirements.
Beta-glucan recovered from mushroom biomass may be evaluated for nutraceutical and related ingredient applications.
Final positioning would require analytical verification and application-specific qualification.
Mineral-balanced digestate from the process may be evaluated as an organic soil amendment.
Regulatory approval and agronomic testing may be required before commercial use.
The draft production model assumes the following preliminary product mix:
The final product mix would depend on pilot yields, market demand, customer qualification and regulatory requirements.
The proposed manufacturing platform includes four principal process-innovation layers.
Enzymatic demineralization is intended to preserve molecular integrity while reducing the intensity of conventional acid and alkaline treatments.
Potential benefits include:
Microwave-assisted kinetics may help reduce processing time and improve control over molecular-weight distribution.
A more consistent molecular-weight profile could support improved batch repeatability and more precisely defined product specifications.
The proposed closed-loop system would recover solvent and water streams for reuse in subsequent production cycles where technically appropriate.
The system is intended to help reduce:
The proposed facility would include in-house analytical testing and batch-release capabilities.
Planned analytical equipment may include:
In-house analysis could reduce dependence on external laboratories, shorten testing timelines and strengthen batch documentation.
The following figures represent indicative targets used in the project’s preliminary comparison with a conventional shellfish-processing baseline:
| Performance metric | Proposed process target | Conventional comparison baseline |
|---|---|---|
| Fresh-water consumption | Approximately 25 L/kg | Approximately 280 L/kg |
| Energy demand | Approximately 6 kWh/kg | Approximately 18 kWh/kg |
| Toxic liquid effluent | Targeting approximately 0 L/kg at the partner site | Approximately 14 L/kg |
| Batch cycle | Approximately 14 hours | Approximately 42 hours |
These figures are not confirmed commercial-performance results. They remain subject to pilot validation, engineering analysis and independent verification.
The proposed 25,000–30,000-square-foot facility would be divided into five connected operational zones.
Approximately 3,000 square feet would be allocated to receiving, inspecting and transferring substrate supplied by Bioferment.tech.
Incoming material would be assessed under documented quality-control procedures before entering production.
Approximately 9,000 square feet would be allocated to climate-controlled fermentation and bioreactor operations.
This zone would support controlled biological growth and biomass production.
Approximately 8,000 square feet would be dedicated to extraction, purification and related processing operations.
The proposed extraction area would be positioned adjacent to a controlled cleanroom environment.
Approximately 2,000 square feet would be allocated to quality-assurance and quality-control operations.
The laboratory would support:
Approximately 2,000 square feet would support controlled packaging, warehousing and shipping.
The packaging environment would be designed to maintain product identity, cleanliness and batch traceability.
Preliminary facility requirements include:
The intended material flow is:
Substrate Receiving → Fermentation → Extraction and Purification → Quality Control → Packaging and Shipping
The final layout would remain subject to site surveys, engineering design and regulatory requirements.
The preliminary $3.5 million Phase 1 capital allocation is structured as follows:
| Investment category | Preliminary allocation | Percentage |
|---|---|---|
| Facility buildout and modular production zones | $1.40 million | 40% |
| Fermentation and bioreactor systems | $0.60 million | 17% |
| Extraction and purification equipment | $0.50 million | 14% |
| QA/QC laboratory and instrumentation | $0.30 million | 9% |
| Utilities, cleanroom and steam connections | $0.30 million | 9% |
| Process automation and control systems | $0.22 million | 6% |
| Installation, commissioning and qualification | $0.18 million | 5% |
| Total proposed capital | $3.50 million | 100% |
Approximately $1.40 million would be allocated to facility improvements and modular operating zones.
Potential requirements include:
Approximately $600,000 would be allocated to fermentation equipment, climate-controlled tanks, control systems and related infrastructure.
Approximately $500,000 would support the proposed extraction and purification train.
Potential equipment may support:
Approximately $300,000 would support laboratory development and analytical instrumentation.
Approximately $300,000 would support utility connections, cleanroom development, steam infrastructure, water loops and related systems.
Approximately $220,000 would support programmable logic controllers, process-control systems and manufacturing-reporting capabilities.
Approximately $180,000 would be allocated to installation, qualification, commissioning and vendor support.
The preliminary capital model also includes access to the proposed Promecens enzymatic-process and standard-operating-procedure package. The final commercial and intellectual-property terms would be defined through formal agreements.
Preliminary management estimates place Year 1 operating expenses at approximately $1.8 million.
| Operating category | Estimated share |
|---|---|
| Labor and employee benefits | 45% |
| Utilities and energy | 25% |
| QA/QC and production consumables | 15% |
| Maintenance and miscellaneous expenses | 15% |
Operating expenses would be funded separately from the proposed capital-expenditure budget.
The preliminary operating plan includes approximately 22 full-time-equivalent positions.
| Department | Preliminary workforce |
|---|---|
| Operations and processing | 10 FTE |
| Fermentation and bioconversion | 6 FTE |
| QA/QC and laboratory operations | 4 FTE |
| Management and administration | 2 FTE |
| Total | 22 FTE |
Workforce expansion would be linked to verified production throughput and commercial demand rather than treated as fixed overhead.
The proposed production platform consists of six stages.
Mushroom substrate and associated mycelium would be received from Bioferment.tech.
Incoming materials may be evaluated for:
The substrate would enter a climate-controlled bioreactor process with an indicative cycle of approximately 72–96 hours.
The preliminary target is to achieve more than two times biomass growth, subject to pilot validation.
Following fermentation, the biomass would be recovered through filtration and washing.
The filtered material may be separated into:
The preliminary model uses an approximately 12% chitin-yield target. Actual yield would depend on feedstock quality and validated process performance.
Recovered chitin would undergo enzymatic and microwave-assisted processing.
The proposed system includes:
The preliminary pharmaceutical-grade target is a degree of deacetylation of at least 98%.
Following deacetylation, the material would be purified and dried according to the intended grade.
Potential drying methods include:
The preliminary finished-product moisture target is below 5%, subject to individual product specifications.
Finished material would undergo analytical testing and formal batch-release review.
The proposed release system may include:
All process parameters remain indicative until confirmed through pilot batches and engineering validation.
The brownfield co-location model is expected to provide several potential advantages compared with a standalone facility.
Direct access to the partner’s substrate line could reduce applicable feedstock-handling costs by approximately 30%.
Potential savings may result from reducing:
Shared access to steam, water, refrigeration and effluent-treatment infrastructure could reduce applicable utility costs by approximately 25%, based on preliminary management estimates.
Where legally permitted, amendments to existing site permits may provide a more efficient pathway than initiating entirely new applications.
The preliminary permit window is estimated at approximately six to nine months.
Cross-training selected personnel across quality assurance, environmental health and safety, warehousing and facility operations could reduce applicable staffing and overhead requirements.
The preliminary model estimates approximately 30% efficiency in relevant shared-workforce functions.
The proposed execution plan targets approximately 12 months from capital deployment to the first commercial shipment.
Indicative period: Months 1–3
Primary activities include:
Required gate: The lease or co-location agreement must be executed and the relevant permit amendments submitted before the next major capital tranche is released.
Indicative period: Months 4–6
Primary activities include:
Required gate: Major equipment must be installed and applicable standard operating procedures approved before commissioning begins.
Indicative period: Months 7–9
Primary activities include:
Required gate: At least three pilot batches must meet defined specifications before commercial release.
Indicative period: Months 10–12
Primary activities include:
Required gate: Qualified anchor-customer demand should be established before Phase 2 expansion is approved.
Risk: Dependence on a single partner substrate line without a finalized long-term agreement.
Proposed mitigation:
Risk: Variability when scaling pharmaceutical-grade extraction from pilot to commercial production.
Proposed mitigation:
Risk: Dependence on one product grade or exposure to changes in specialized chitosan pricing.
Proposed mitigation:
Risk: Permit delays or changes in pharmaceutical, cosmetic, food or environmental requirements.
Proposed mitigation:
Risk: Yield or throughput variation during commissioning and the initial commercial-production period.
Proposed mitigation:
Subject to pilot validation, customer qualification, commercial agreements and confirmatory due diligence, the project’s preliminary management targets include:
These figures are illustrative management estimates. They are not guaranteed financial outcomes.
The proposed forward plan includes four immediate priorities:
The proposed mushroom chitosan biorefinery combines an established substrate source, modular extraction technology, multiple product grades and potential co-product revenue streams.
If validated through pilot testing and technical, regulatory, commercial and financial due diligence, the project could establish a scalable platform for supplying non-shellfish chitosan to pharmaceutical, cosmetic, nutraceutical, agricultural and industrial markets.
The opportunity is based on three core objectives:
The modular approach is intended to allow the facility to validate production, qualify customers and measure commercial demand before committing capital to a larger expansion.
Promecens Entosystems and Shield Nutraceuticals welcome discussions with qualified institutional, technical and commercial partners regarding the proposed Phase 1 development.
Detailed engineering specifications, vendor quotations, intellectual-property materials and site information may be made available to qualified parties under an appropriate confidentiality agreement.
Abhi Chauhan
Chief Executive, Promecens
Steve Nice
Chief Executive, Shield Nutraceuticals
Email: abhi@chitosanglobal.com
Website: ChitosanGlobal.com
This article presents a preliminary proposal for a Phase 1 mushroom chitosan biorefinery.
All facility specifications, capital requirements, operating expenses, production targets, process-performance figures, pricing assumptions, cost-saving estimates, environmental metrics, revenue projections, EBITDA estimates and payback periods are preliminary management estimates.
They remain subject to:
Nothing in this article constitutes an offer to sell securities, a solicitation of investment, a guarantee of product performance or a guarantee of financial results.
What would you like help with?
Take the first step towards a happier gut. Get 5% OFF your next purchase of DigestShield.
